BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 27391062)

  • 1. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.
    Wang CY; Guo ST; Wang JY; Yan XG; Farrelly M; Zhang YY; Liu F; Yari H; La T; Lei FX; Jin L; Zhang XD; Jiang CC
    Oncotarget; 2016 Aug; 7(31):49597-49610. PubMed ID: 27391062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BAG3-dependent expression of Mcl-1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922.
    Wang CY; Guo ST; Croft A; Yan XG; Jin L; Zhang XD; Jiang CC
    Mol Carcinog; 2018 Feb; 57(2):284-294. PubMed ID: 29068469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.
    Wang CY; Guo ST; Wang JY; Liu F; Zhang YY; Yari H; Yan XG; Jin L; Zhang XD; Jiang CC
    Mol Cancer Ther; 2016 Mar; 15(3):448-59. PubMed ID: 26832792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer.
    Bao XH; Takaoka M; Hao HF; Fukazawa T; Yamatsuji T; Sakurama K; Takigawa N; Nakajima M; Fujiwara T; Naomoto Y
    Oncol Rep; 2013 Jan; 29(1):45-50. PubMed ID: 23064324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
    Park KS; Yang H; Choi J; Seo S; Kim D; Lee CH; Jeon H; Kim SW; Lee DH
    Cancer Lett; 2017 Oct; 406():47-53. PubMed ID: 28797845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.
    Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R
    Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.
    Chen SM; Guo CL; Shi JJ; Xu YC; Chen Y; Shen YY; Su Y; Ding J; Meng LH
    Int J Cancer; 2014 Nov; 135(10):2462-74. PubMed ID: 24706460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
    Gandhi N; Wild AT; Chettiar ST; Aziz K; Kato Y; Gajula RP; Williams RD; Cades JA; Annadanam A; Song D; Zhang Y; Hales RK; Herman JM; Armour E; DeWeese TL; Schaeffer EM; Tran PT
    Cancer Biol Ther; 2013 Apr; 14(4):347-56. PubMed ID: 23358469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells.
    Zitzmann K; Ailer G; Vlotides G; Spoettl G; Maurer J; Göke B; Beuschlein F; Auernhammer CJ
    Int J Oncol; 2013 Dec; 43(6):1824-32. PubMed ID: 24100469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins.
    Smith JR; de Billy E; Hobbs S; Powers M; Prodromou C; Pearl L; Clarke PA; Workman P
    Oncogene; 2015 Jan; 34(1):15-26. PubMed ID: 24292678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
    Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
    Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.
    Wainberg ZA; Anghel A; Rogers AM; Desai AJ; Kalous O; Conklin D; Ayala R; O'Brien NA; Quadt C; Akimov M; Slamon DJ; Finn RS
    Mol Cancer Ther; 2013 Apr; 12(4):509-19. PubMed ID: 23395886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922.
    Kühnel A; Schilling D; Combs SE; Haller B; Schwab M; Multhoff G
    Cells; 2019 Sep; 8(10):. PubMed ID: 31569342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat Shock Protein 90 Inhibitors AUY922, BIIB021 and SNX5422 Induce Bim-mediated Death of Thyroid Carcinoma Cells.
    Kim SH; Cho YK; Huh JH; Kang JG; Ihm SH; Choi MG; Lee SJ
    Anticancer Res; 2020 Nov; 40(11):6137-6150. PubMed ID: 33109551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells.
    Park KS; Hong YS; Choi J; Yoon S; Kang J; Kim D; Lee KP; Im HS; Lee CH; Seo S; Kim SW; Lee DH; Park SR
    BMB Rep; 2018 Dec; 51(12):660-665. PubMed ID: 30591093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
    Guo Y; Chekaluk Y; Zhang J; Du J; Gray NS; Wu CL; Kwiatkowski DJ
    J Pathol; 2013 May; 230(1):17-27. PubMed ID: 23401075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cells.
    Bai J; Zhou G; Qiu Y; Hu Y; Liu J; Zhao J; Zhang S; Zhang J
    Cancer Sci; 2017 Jun; 108(6):1177-1184. PubMed ID: 28301080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells.
    Taniguchi H; Hasegawa H; Sasaki D; Ando K; Sawayama Y; Imanishi D; Taguchi J; Imaizumi Y; Hata T; Tsukasaki K; Uno N; Morinaga Y; Yanagihara K; Miyazaki Y
    Cancer Sci; 2014 Dec; 105(12):1601-8. PubMed ID: 25263741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chaperone-mediated autophagy degradation of IGF-1Rβ induced by NVP-AUY922 in pancreatic cancer.
    Xue N; Lai F; Du T; Ji M; Liu D; Yan C; Zhang S; Yu X; Jin J; Chen X
    Cell Mol Life Sci; 2019 Sep; 76(17):3433-3447. PubMed ID: 30980109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.